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additional palliative measures remain essential for adequate 
pain control. 
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Purpose/Objective: Graves’ Ophthalmopathy is the 
commonest extrathryoidal manifestation of Graves’ disease. 
The underlying pathogenesis is believed to be autoimmune-
related leading to excessive infiltration of lymphocytes and 
excessive production of hydrophilic glycosaminoglycans and 
subsequently expansion of retro-orbital tissues and 
enlargement of extraocular muscles. Treatment options 
include steroid therapy, corrective/decompressive surgery, 
radiation therapy or combination of these approaches. Our 
purpose is to investigate if retro-orbital irradiation with 
Inverse VMAT IMRT planning produced better target coverage 
and dose sparing to adjacent normal structures as compared 
with Forward IMRT and 3D conformal for patients with 
bilateral Graves’ Ophthalmopathy. 
Materials and Methods: Fourteen consecutive patients 
diagnosed with bilateral Graves’ Ophthalmopathy were 
prospectively recruited into this study. An individual Inverse 
VMAT IMRT planning, Forward IMRT and 3D conformal plan 
was created for each patient. Conformity Index (CI), 
Homogeneity Index (HI) and other dosimetric parameters of 
the targets and organs-at-risk (OAR) were compared between 
the different techniques. Statistical analysis was T-student. 
Results: CI generated by Inverse VMAT IMRT planning was 
superior to that produced by Forward IMRT and 3D conformal 
(p<.001 for both respectively). As expected Forward IMRT 
was superior to 3D conformal (p=.007). However the 
differences in the HI was not significant.  Inverse VMAT IMRT 
planning resulted in better OARs dose sparing (globe, lens, 
retina, lacrimal gland, optic nerve) with the exception of the 
optic chiasm that received a higher dose. The differences in 
the dose sparing of the OARs didn’t shown a significant 
difference when comparing Forward IMRT to 3D conformal. 
 Conclusions: Inverse VMAT IMRT planning is superior to 
Forward IMRT and 3D conformal for bilateral Graves’ 
Ophthalmopathy treatment in virtue of the benefit on the 
target coverage, better CI with similar HI, and better sparing 
of the OARs, despite an increase in treatment planning and 
delivery time, consumption of monitor units and a slightly 
increased but clinically negligible dose to some surrounding 
structures. 
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Purpose/Objective: To identify predictive factors of local 
control (LC) and develop a model for estimating tumor 
response in patients with cranial and extracranial 
oligometastases treated by hypofractionated stereotactic 
radiotherapy (SBRT/SRS). 
Materials and Methods: Clinical data from 79 patients who 
received hypofractionated SBRT/SRS for cranial and 
extracranial oligometastases (£ 5 lesions), with different 
primary tumor, primary histology, and metastatic lesions 
(lung, liver, brain, adrenal gland) were collected. Maximum 
local response was evaluated according to RECIST criteria. 
Univariate and multivariate analysis were performed to 
identify best significant predictors for local control. A dose-
response model estimating the maximum tumor response to 
treatment has been defined. 
Results: Main histological type was adenocarcinoma (62%). 
The most frequent primary tumor was colorectal cancer 
(44%); main oligometastastic sites were lung (58%), brain 
(22%), liver (15%), and adrenal gland (5%). The Median 
prescribed BED10 was 71.8 Gy (range, 45-100.8). The overall 
response rate was 61%. Median LC was 27.9 months, with a 2 
years LC rate of 60%. Univariate analysis defined 2 patient-
inherent factors indipendently related to LC: primary 
colorectal cancer (negative predictor, p=0.01), and the dose 
normalized to pretreatment lesion volume (ND; see equation) 
(positive predictor, p=0.02).Significant variables for LC on 
univariate analysis were tested in multivariate analysis. A 
logistic linear generalized model was fitted to data (figure). 
The model performed well for the ND (p=0.004). The 
evaluation method shows the Poisson model as good 
compromise between prediction power (TD50=16.1, 
g50=0.53; AIC=97.43, AUC=0.7045) and model simplicity. 
 
 
Figure: plot of the three dose-response models fitted to data, 
Logit (blue), LogLogit (red), Poisson (green). Confidence 
intervals for TCP and ND (BED/logVol) have been calculated 
by using bootstrapping 5000 sample series based on the initial 
dataset. 
Conclusions: The proposed model performed well, it was 
internal successfully validated, and showed the ability to 
predict a dose-response relationship between the prescribed 
dose, the lesion volume and the maximum response to 
hypofractionated stereotactic radiotherapy for 
oligometastatic patients. Future researches should be 
directed to test the model on more numerous and prognostic 
variables-based series of patients. 
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Purpose/Objective: Modern systemic tumour therapy 
ameliorates the prognosis of diverse malignancies. The 
